Upfront use of gemtuzumab ozogamicin in young children with CD33-positive AML.
Sayar
Dror
D
Pediatric Hemato-Oncology Unit, Dana Children's Hospital (affiliated to the Sackler Faculty of Medicine), Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. drorsayar@gmail.com
Burstein
Yoav
Y
Bielorai
Bela
B
Toren
Amos
A
Dvir
Rina
R
D000617:Aminoglycosides / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000937:Antigen-Antibody Reactions; D015703:Antigens, CD / Q000276:immunology*; D015214:Antigens, Differentiation, Myelomonocytic / Q000276:immunology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D000079982:Gemtuzumab; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D012008:Recurrence; D063268:Sialic Acid Binding Ig-like Lectin 3
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; C571163:CD33 protein, human; D063268:Sialic Acid Binding Ig-like Lectin 3; D000079982:Gemtuzumab